Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 3/2012

01-03-2012 | Systematic review

Measures of health-related quality of life in diabetes-related foot disease: a systematic review

Authors: F. R. A. Hogg, G. Peach, P. Price, M. M. Thompson, R. J. Hinchliffe

Published in: Diabetologia | Issue 3/2012

Login to get access

Abstract

Aims/hypothesis

Patient-reported outcome measures (PROMs) are increasingly used as key performance indicators in chronic illness. We sought to review the value of these tools in assessing health-related quality of life (HRQOL) in patients with diabetes-related foot disease and identify the impact of each foot problem on life quality.

Methods

A systematic review of literature on HRQOL PROMs in diabetes-related foot disease was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The quality of eligible studies was evaluated within pre-existing criteria.

Results

53 studies written between 1995 and 2010 met the inclusion criteria. A variety of HRQOL PROMs were used. Disease-specific tools were better than generic at quantifying temporal changes in life quality and showed greater sensitivity to ulcer/neuropathic severity. No studies have simultaneously evaluated disease-specific tools. Generic and utility HRQOL PROMs are frequently used as secondary outcome measures in randomised trials and cost–utility analysis.
HRQOL is depressed in diabetes, further impaired by the presence of foot disease. Ulcer healing is associated with improvements in HRQOL. Patients with active ulceration report poorer HRQOL than those whom have undergone successful minor lower extremity amputation (LEA) but there is a paucity of quality data on HRQOL outcomes for diabetes-related LEA.

Conclusions/interpretation

No one PROM was identified as a ‘gold standard’ for assessing HRQOL in diabetes-related foot disease. Specific areas for further development include the most valid HRQOL PROM with disease-specific content; HRQOL outcomes in minor and major amputations and the role of HRQOL tools in routine clinical care.
Literature
1.
Hinchliffe RJ, Valk GD, Apelqvist J et al (2008) A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev 24(Suppl 1):S119–S144PubMedCrossRef
2.
3.
Cornish D, Holterhues C, van de Poll-Franse LV, Coebergh JW, Nijsten T (2009) A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol 20(Suppl 6):vi51–vi58PubMedCrossRef
4.
Fitzpatrick R, Davey C, Buxton MJ, Jones DR (1998) Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess 2:i–iv, 1–74PubMed
5.
Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34PubMedCrossRef
6.
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006–1012PubMedCrossRef
7.
Davies M, Brophy S, Williams R, Taylor A (2006) The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 29:1518–1522PubMedCrossRef
8.
Price P, Harding K (2004) Cardiff Wound Impact Schedule: the development of a condition-specific questionnaire to assess health-related quality of life in patients with chronic wounds of the lower limb. Int Wound J 1:10–17PubMedCrossRef
9.
Nabuurs-Franssen MH, Huijberts MS, Nieuwenhuijzen Kruseman AC, Willems J, Schaper NC (2005) Health-related quality of life of diabetic foot ulcer patients and their caregivers. Diabetologia 48:1906–1910PubMedCrossRef
10.
Ribu L, Birkeland K, Hanestad BR, Moum T, Rustoen T (2008) A longitudinal study of patients with diabetes and foot ulcers and their health-related quality of life: wound healing and quality-of-life changes. J Diabetes Complications 22:400–407PubMedCrossRef
11.
Valensi P, Girod I, Baron F, Moreau-Defarges T, Guillon P (2005) Quality of life and clinical correlates in patients with diabetic foot ulcers. Diabetes Metab 31:263–271PubMedCrossRef
12.
Abetz L, Sutton M, Brady L, McNulty P, Gagnon D (2002) The Diabetic Foot Ulcer Scale (DFS): a quality of life instrument for use in clinical trials. Pract Diabetes Int 19:167–175CrossRef
13.
Ribu L, Hanestad BR, Moum T, Birkeland K, Rustoen T (2007) Health-related quality of life among patients with diabetes and foot ulcers: association with demographic and clinical characteristics. J Diabetes Complications 21:227–236PubMedCrossRef
14.
Ribu L, Hanestad BR, Moum T, Birkeland K, Rustoen T (2007) A comparison of the health-related quality of life in patients with diabetic foot ulcers, with a diabetes group and a nondiabetes group from the general population. Qual Life Res 16:179–189PubMedCrossRef
15.
Ribu L, Rustoen T, Birkeland K, Hanestad BR, Paul SM, Miaskowski C (2006) The prevalence and occurrence of diabetic foot ulcer pain and its impact on health-related quality of life. J Pain 7:290–299PubMedCrossRef
16.
Huang IC, Hwang CC, Wu MY, Lin W, Leite W, Wu AW (2008) Diabetes-specific or generic measures for health-related quality of life? Evidence from psychometric validation of the D-39 and SF-36. Value Health 11:450–461PubMedCrossRef
17.
Pakarinen TK, Laine HJ, Maenpaa H, Mattila P, Lahtela J (2009) Long-term outcome and quality of life in patients with Charcot foot. Foot Ankle Surg 15:187–191PubMedCrossRef
18.
Sochocki MP, Verity S, Atherton PJ et al (2008) Health related quality of life in patients with Charcot arthropathy of the foot and ankle. Foot Ankle Surg 14:11–15PubMedCrossRef
19.
Jaksa PJ, Mahoney JL (2010) Quality of life in patients with diabetic foot ulcers: validation of the Cardiff Wound Impact Schedule in a Canadian population. Int Wound J 7(6):502–507PubMedCrossRef
20.
Currie CJ, Poole CD, Woehl A et al (2006) The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 49:2272–2280PubMedCrossRef
21.
Ware JE Jr, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME (2007) User’s manual for the SF-36v2 health survey, 2nd edn. QualityMetric, Inc, Lincoln
22.
Selvarajah D, Gandhi R, Emery CJ, Tesfaye S (2010) Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care 33:128–130PubMedCrossRef
23.
Swislocki A, Orth M, Bales M et al (2010) A randomized clinical trial of the effectiveness of photon stimulation on pain, sensation, and quality of life in patients with diabetic peripheral neuropathy. J Pain Symptom Manage 39:88–99PubMedCrossRef
24.
Armstrong DG, Lavery LA, Wrobel JS, Vileikyte L (2008) Quality of life in healing diabetic wounds: does the end justify the means? J Foot Ankle Surg 47:278–282PubMedCrossRef
25.
Rauck RL, Shaibani A, Biton V, Simpson J, Koch B (2007) Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain 23:150–158PubMedCrossRef
26.
Rosenstock J, Tuchman M, LaMoreaux L, Sharma U (2004) Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110:628–638PubMedCrossRef
27.
Jeffcoate WJ, Price PE, Phillips CJ et al (2009) Randomised controlled trial of the use of three dressing preparations in the management of chronic ulceration of the foot in diabetes. Health Technol Assess 13:1–86, iii–ivPubMed
28.
Benbow SJ, Wallymahmed ME, MacFarlane IA (1998) Diabetic peripheral neuropathy and quality of life. QJM 91:733–737PubMedCrossRef
29.
Meijer JW, Trip J, Jaegers SM et al (2001) Quality of life in patients with diabetic foot ulcers. Disabil Rehabil 23:336–340PubMedCrossRef
30.
Peters EJ, Childs MR, Wunderlich RP, Harkless LB, Armstrong DG, Lavery LA (2001) Functional status of persons with diabetes-related lower-extremity amputations. Diabetes Care 24:1799–1804PubMedCrossRef
31.
Vileikyte L, Peyrot M, Bundy C et al (2003) The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care 26:2549–2555PubMedCrossRef
32.
National Institute for Health and Clinical Excellence (2008) Guide to the methods of technology appraisal, 2008. NICE, London
33.
Carrington AL, Mawdsley SK, Morley M, Kincey J, Boulton AJ (1996) Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 32:19–25PubMedCrossRef
34.
Belury MA, Mahon A, Banni S (2003) The conjugated linoleic acid (CLA) isomer, t10c12-CLA, is inversely associated with changes in body weight and serum leptin in subjects with type 2 diabetes mellitus. J Nutr 133:257S–260SPubMed
35.
Vinik EJ, Hayes RP, Oglesby A et al (2005) The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 7:497–508PubMedCrossRef
36.
Vinik EJ, Paulson JF, Ford-Molvik SL, Vinik AI (2008) German-translated Norfolk quality of life (QOL-DN) identifies the same factors as the English version of the tool and discriminates different levels of neuropathy severity. J Diabetes Sci Technol 2:1075–1086PubMed
37.
Hjelm K, Nyberg P, Apelqvist J (2002) Gender influences beliefs about health and illness in diabetic subjects with severe foot lesions. J Adv Nurs 40:673–684PubMedCrossRef
38.
Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA (2004) Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 61:160–173PubMed
39.
Brod M (1998) Quality of life issues in patients with diabetes and lower extremity ulcers: patients and care givers. Qual Life Res 7:365–372PubMedCrossRef
40.
Pinzur MS, Evans A (2003) Health-related quality of life in patients with Charcot foot. Am J Orthop (Belle Mead NJ) 32:492–496
41.
Eckman MH, Greenfield S, Mackey WC et al (1995) Foot infections in diabetic patients. Decision and cost-effectiveness analyses. JAMA 273:712–720PubMedCrossRef
42.
Winkley K, Stahl D, Chalder T, Edmonds ME, Ismail K (2009) Quality of life in people with their first diabetic foot ulcer: a prospective cohort study. J Am Podiatr Med Assoc 99:406–414PubMed
43.
Ragnarson Tennvall G, Apelqvist J (2000) Health-related quality of life in patients with diabetes mellitus and foot ulcers. J Diabetes Complicat 14:235–241PubMedCrossRef
44.
Tennvall GR, Apelqvist J, Eneroth M (2000) Costs of deep foot infections in patients with diabetes mellitus. PharmacoEconomics 18:225–238PubMedCrossRef
45.
Boutoille D, Feraille A, Maulaz D, Krempf M (2008) Quality of life with diabetes-associated foot complications: comparison between lower-limb amputation and chronic foot ulceration. Foot Ankle Int 29:1074–1078PubMedCrossRef
46.
Tang TS, Brown MB, Funnell MM, Anderson RM (2008) Social support, quality of life, and self-care behaviors among African Americans with type 2 diabetes. Diabetes Educ 34:266–276PubMedCrossRef
47.
Garay-Sevilla ME, Nava LE, Malacara JM et al (1995) Adherence to treatment and social support in patients with non-insulin dependent diabetes mellitus. J Diabetes Complications 9:81–86PubMedCrossRef
48.
Davies S, Gibby O, Phillips C, Price P, Tyrrell W (2000) The health status of diabetic patients receiving orthotic therapy. Qual Life Res 9:233–240PubMedCrossRef
49.
Rerkasem K, Kosachunhanun N, Tongprasert S, Guntawongwan K (2009) A multidisciplinary diabetic foot protocol at Chiang Mai University Hospital: cost and quality of life. Int J Low Extrem Wounds 8:153–156PubMedCrossRef
50.
McHorney CA, Ware JE Jr, Rogers W, Raczek AE, Lu JF (1992) The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care 30(5 Suppl):MS253–MS265PubMedCrossRef
51.
Armstrong DG, Lavery LA, Fleischli JG, Gilham KA (1997) Is electrical stimulation effective in reducing neuropathic pain in patients with diabetes? J Foot Ankle Surg 36:260–263PubMedCrossRef
52.
Backonja M, Beydoun A, Edwards KR et al (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280:1831–1836PubMedCrossRef
53.
Piaggesi A, Schipani E, Campi F et al (1998) Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcers: a randomized trial. Diabet Med 15:412–417PubMedCrossRef
54.
Coffey JT, Brandle M, Zhou H et al (2002) Valuing health-related quality of life in diabetes. Diabetes Care 25:2238–2243PubMedCrossRef
55.
Dhawan V, Spratt KF, Pinzur MS, Baumhauer J, Rudicel S, Saltzman CL (2005) Reliability of AOFAS diabetic foot questionnaire in Charcot arthropathy: stability, internal consistency, and measurable difference. Foot Ankle Int 26:717–731PubMed
56.
Evans AR, Pinzur MS (2005) Health-related quality of life of patients with diabetes and foot ulcers. Foot Ankle Int 26:32–37PubMed
57.
Willrich A, Pinzur M, McNeil M, Juknelis D, Lavery L (2005) Health related quality of life, cognitive function, and depression in diabetic patients with foot ulcer or amputation. A preliminary study. Foot Ankle Int 26:128–134PubMed
58.
Goodridge D, Trepman E, Sloan J et al (2006) Quality of life of adults with unhealed and healed diabetic foot ulcers. Foot Ankle Int 27:274–280PubMed
59.
Tarride JE, Gordon A, Vera-Llonch M, Dukes E, Rousseau C (2006) Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther 28:1922–1934PubMedCrossRef
60.
Tolle T, Xu X, Sadosky AB (2006) Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications 20:26–33PubMedCrossRef
61.
Casellini CM, Barlow PM, Rice AL et al (2007) A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-β inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care 30:896–902PubMedCrossRef
62.
Lewko J, Politynska B, Kochanowicz J et al (2007) Quality of life and its relationship to the degree of illness acceptance in patients with diabetes and peripheral diabetic neuropathy. Adv Med Sci 52(Suppl 1):144–146PubMed
63.
Nelson SC, Little ER Jr (2007) The 36-item Short-Form Health Survey outcome evaluation for multiple lower-extremity nerve decompressions in diabetic peripheral neuropathy: a pilot study. J Am Podiatr Med Assoc 97:121–125PubMed
64.
Happich M, John J, Stamenitis S, Clouth J, Polnau D (2008) The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002—results from the Diabetic Microvascular Complications (DIMICO) study. Diabetes Res Clin Pract 81:223–230PubMedCrossRef
65.
Lavery LA, Murdoch DP, Williams J, Lavery DC (2008) Does anodyne light therapy improve peripheral neuropathy in diabetes? A double-blind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy. Diabetes Care 31:316–321PubMedCrossRef
66.
Lincoln NB, Radford KA, Game FL, Jeffcoate WJ (2008) Education for secondary prevention of foot ulcers in people with diabetes: a randomised controlled trial. Diabetologia 51:1954–1961PubMedCrossRef
67.
Mittlmeier T, Klaue K, Haar P, Beck M (2010) Should one consider primary surgical reconstruction in charcot arthropathy of the feet? Clin Orthop Relat Res 468:1002–1011PubMedCrossRef
68.
Spiegelhalter DJ, Gore SM, Fitzpatrick R, Fletcher AE, Jones DR, Cox DR (1992) Quality of life measures in health care. III: Resource allocation. BMJ 305:1205–1209PubMedCrossRef
69.
Bann CM, Fehnel SE, Gagnon DD (2003) Development and validation of the Diabetic Foot Ulcer Scale-short form (DFS-SF). PharmacoEconomics 21:1277–1290PubMedCrossRef
Metadata
Title
Measures of health-related quality of life in diabetes-related foot disease: a systematic review
Authors
F. R. A. Hogg
G. Peach
P. Price
M. M. Thompson
R. J. Hinchliffe
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2372-5

Other articles of this Issue 3/2012

Diabetologia 3/2012 Go to the issue

Meta-analysis

Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis

Article

Increased metabolic rate and insulin sensitivity in male mice lacking the carcino-embryonic antigen-related cell adhesion molecule 2

Article

Retinopathy in old persons with and without diabetes mellitus: the Age, Gene/Environment Susceptibility—Reykjavik Study (AGES-R)

Letter

Women develop diabetes at higher BMIs than men

Article

Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data

Article

INS GFP/w human embryonic stem cells facilitate isolation of in vitro derived insulin-producing cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits